Lista de obras - Kateřina Machová Poláková

AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome

artículo científico publicado en 2018

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

artículo científico publicado en 2020

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

artículo científico publicado en 2010

BCR-ABL mutations in chronic myeloid leukemia–Not only detection

scientific article published on 01 August 2008

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

artículo científico publicado en 2018

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.

artículo científico publicado en 2015

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

artículo científico publicado en 2010

Control genes in international standardization of real-time RT-PCR for BCR-ABL.

artículo científico publicado en 2008

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

artículo científico publicado en 2013

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

artículo científico publicado en 2010

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

scientific article published on 25 April 2016

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

artículo científico publicado en 2018

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

artículo científico publicado en 2013

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia

artículo científico publicado en 2016

Expression patterns of microRNAs associated with CML phases and their disease related targets

artículo científico publicado en 2011

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

artículo científico publicado en 2017

High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain

artículo científico publicado en 2008

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

artículo científico publicado en 2011

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

artículo científico publicado en 2022

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

artículo científico publicado en 2016

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

artículo científico publicado en 2016

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

artículo científico publicado en 2015

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.

artículo científico publicado en 2017

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

artículo científico publicado en 2014

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

artículo científico publicado en 2016

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

artículo científico publicado en 2013

Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions ⬇️

scientific article published on 01 July 2020

Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.

artículo científico publicado en 2016

Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences.

artículo científico publicado en 2012

Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.

artículo científico publicado en 2009

Role of epigenetics in chronic myeloid leukemia

artículo científico

Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells

artículo científico publicado en 2021

Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining

artículo científico publicado en 2021

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2024

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

artículo científico publicado en 2011

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

artículo científico publicado en 2013

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

scientific article published on 13 September 2018

Lista de obras de Kateřina Machová Poláková

AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

BCR-ABL mutations in chronic myeloid leukemia–Not only detection

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

Control genes in international standardization of real-time RT-PCR for BCR-ABL.

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia

Expression patterns of microRNAs associated with CML phases and their disease related targets

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions ⬇️

Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.

Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences.

Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.

Role of epigenetics in chronic myeloid leukemia

Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells

Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels